Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Sustainability Profile
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., commonly referred to as Sun-Novo, is a leading player in the pharmaceutical industry, headquartered in Beijing, China. Established in 2003, the company has made significant strides in drug discovery and development, focusing on innovative solutions for various therapeutic areas, including oncology and cardiovascular diseases. With a strong presence in both domestic and international markets, Sun-Novo is renowned for its commitment to research and development, offering a diverse portfolio of core products and services. Their unique approach combines advanced technology with a deep understanding of patient needs, positioning them as a trusted partner in the pharmaceutical landscape. Notable achievements include successful collaborations and a growing pipeline of novel therapeutics, solidifying Sun-Novo's reputation as a key contributor to global health advancements.
DitchCarbon Score
How does Beijing Sun-Novo Pharmaceutical Research Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.'s score of 22 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.'s reported carbon emissions
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., headquartered in China (CN), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments towards reducing its carbon footprint. As there are no emissions data or reduction initiatives available, it is unclear how Beijing Sun-Novo Pharmaceutical Research Co., Ltd. is addressing climate change within the pharmaceutical industry context. The absence of emissions reporting may reflect a broader trend in the sector, where companies are increasingly being urged to disclose their environmental impact and set ambitious targets in line with global climate goals. In summary, without specific emissions data or reduction commitments, it is challenging to assess Beijing Sun-Novo Pharmaceutical Research Co., Ltd.'s climate performance or its alignment with industry standards for sustainability.
How Carbon Intensive is Beijing Sun-Novo Pharmaceutical Research Co., Ltd.'s Industry?
How Carbon Intensive is Beijing Sun-Novo Pharmaceutical Research Co., Ltd.'s Location?
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
